Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus
NCT ID: NCT01235819
Last Updated: 2016-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
20 participants
INTERVENTIONAL
2010-11-30
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
NCT01937598
Effectiveness of Sitagliptin in Glycemic Control in Real World
NCT01316835
Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?
NCT05359341
Vascular Effects of Sitagliptin in Diabetes Mellitus
NCT01096277
Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes
NCT00971659
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Insulin alone
Type 1 DM only on Insulin
Insulin
Exenatide Sitagliptin
Insulin and Exenatide
Newly detected Type 1 DM on Insulin and exenatide
Exenatide
Exenatide 10 micrograms daily twice
Insulin and Sitagliptin
Newly detected Type 1 DM using Insulin and Sitagliptin
Sitagliptin
Sitagliptin 100 mg per day oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Insulin
Exenatide Sitagliptin
Sitagliptin
Sitagliptin 100 mg per day oral
Exenatide
Exenatide 10 micrograms daily twice
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* GAD Antibody+ or Stimulated C peptide\<0.5 ng/ml
* Ketosis at onset
* Age \< 30 yr
Exclusion Criteria
* Pancreas disease
* Significant systemic disease
12 Years
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Command Hospital, India
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
KVS Hari Kumar
Endocrinologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
The Commandant, MD
Role: STUDY_DIRECTOR
Command Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Command Hospital
Lucknow, Uttar Pradesh, India
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hari Kumar KV, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract. 2013 May;100(2):e55-8. doi: 10.1016/j.diabres.2013.01.020. Epub 2013 Mar 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DM/CHCC/03/2010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.